Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/664Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | BUILDERS, Modupe I. | - |
| dc.contributor.author | SIMEON, Joseph Oyepata | - |
| dc.contributor.author | OGUNDEKO, Timothy Olugbenga | - |
| dc.contributor.author | BUILDERS, Philip | - |
| dc.date.accessioned | 2021-12-03T12:27:07Z | - |
| dc.date.available | 2021-12-03T12:27:07Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.issn | 663-421X | - |
| dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/664 | - |
| dc.description.abstract | The coronavirus disease 2019 (COVID-19) is a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that is ravaging the world. Therefore, the need to find new preventive and therapeutic drug at the earliest possible time additionally to the implementation of preventive measures such as early detection, isolation and treatment of cases as well as minimization of transmission through physical interaction. Moreover, specific vaccines and yet effective treatment that target the 2019. This review focuses on the use of antimalarial drugs as therapeutics interventions for COVID-19. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | SUMERIANZ JOURNAL OF MEDICAL AND HEALTHCARE (SJMH) Vol. 3 No. 12 | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.title | Antimalarial Drugs and COVID -19 | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Research Articles | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Antimalarial Drugs and COVID -19.pdf | 766.47 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.